ImmunityBio Aktie
WKN DE: A2QQ2E / ISIN: US45256X1037
|
07.04.2026 01:41:34
|
Why ImmunityBio Stock Slumped on Monday
Cancer-focused biotech ImmunityBio (NASDAQ: IBRX) hasn't been in the good graces of a top regulator lately, and the latest development in that story on Monday was discouraging for investors. Numerous shareholders sold out of the stock to sink it by slightly over 3% that trading session.That regulator is the U.S. Food and Drug Administration (FDA). In mid-March, it sent ImmunityBio a warning letter stating that the biotech's recent promotional materials for cancer immunotherapy drug Anktiva were "false or misleading." Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ImmunityBio Inc Registered Shs
| Keine Nachrichten verfügbar. |
Analysen zu ImmunityBio Inc Registered Shs
Aktien in diesem Artikel
| ImmunityBio Inc Registered Shs | 5,88 | -6,76% |
|